The decision to out-license ARV-806 signals a strategic retreat from a high-profile KRAS G12D program, likely viewed negatively by the market given the $499M market cap and 62% analyst bullishness. Monitor for any partnership announcement or further pipeline cuts; cash runway into H2 2028 provides some buffer but does not offset the development setback.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $7.70entry
- T+1 · 6mo ago +0.52%α +0.12% · $7.74
- T+5 · 5mo ago −9.35%α −5.53% · $6.98
- T+20 · 5mo ago +8.96%α +9.96% · $8.39
- T+60 · 3mo ago +20.00%α +17.50% · $9.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose escalation trial for ARV-806 (KRAS G12D) and then seek an out-licensing partner for further development. The company also furnished an investor presentation for the Jefferies Global Healthcare Conference. Cash runway extends into H2 2028.
Key Facts
- Arvinas is deprioritizing ARV-806, its KRAS G12D program, after completing Phase 1 dose escalation enrollment in Q2 2026.
- The company plans to out-license any further clinical trials (dose expansion or combination) for ARV-806.
- Cash, cash equivalents, and marketable securities as of March 31, 2026 are expected to fund operations into H2 2028.
- An investor presentation was furnished for the Jefferies Global Healthcare Conference on June 3, 2026.
Financial Impact
Pipeline de-prioritization of ARV-806, a key clinical-stage asset, reduces the company's internal development scope and may impair perceived pipeline value. No financial terms of a potential out-license were disclosed.
Risk Factors
- Failure to secure a favorable out-licensing deal for ARV-806 could result in full program write-off.
- Pipeline narrowing increases reliance on remaining programs (e.g., ARV-471, ARV-110), heightening binary risk.
- Cash burn rate may accelerate if no partnership income materializes, potentially requiring dilutive financing before H2 2028.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-039818 |
| Document: 0001628280-26-039818-index-headers.html | 0001628280-26-039818 |
| Document: 0001628280-26-039818-index.html | 0001628280-26-039818 |
| Document: 0001628280-26-039818.txt | 0001628280-26-039818 |
Track record
21 reports on ARVN
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Viewing Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers